Fulvestrant Injection
Product Images NDC 71731-6121

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 71731-6121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (M01 Fig 01)

An instructional diagram illustrating the preparation of an injection. It shows detaching a cap by twisting to access the vial, with labeled parts A, B, and C depicting the vial cap components. This image is likely related to the use of Fulvestrant 50 mg/mL injection for intramuscular administration.*

FDA Label Image

Figure 2 (M01 Fig 02)

An instructional illustration showing how to prepare a Fulvestrant injection. It depicts a hand attaching a syringe needle to a vial adapter and then how to attach the adapter to the vial, indicating steps A, B, and C for proper assembly.*

FDA Label Image

Figure 3 (M01 Fig 03)

Illustration showing a gloved hand holding a vial and a syringe, demonstrating the preparation of an injection. The image depicts the syringe being inserted into the vial to withdraw medication, illustrating the technique typically used for intramuscular injection preparation.*

FDA Label Image

Figure 4 (M01 Fig 04)

An illustration showing the components of an intramuscular injection syringe with a detachable needle. The image highlights the needle tip detail, the syringe barrel, and the plunger mechanism used for administering the injection.*

FDA Label Image

Figure 5 (M01 Fig 05)

An instructional illustration showing a gloved hand holding a syringe for intramuscular injection. The image includes arrows indicating the correct motion or technique to use during the injection process.*

FDA Label Image

Figure 6 (M01 Fig 06)

Chemical structure of fulvestrant showing its steroid backbone with hydroxyl groups and sulfonyl-containing side chain featuring trifluoromethyl groups.*

FDA Label Image

Figure 7 (M01 Fig 07)

A line graph titled 'Progression Free Survival (ITT Population)' comparing the proportion of patients progression-free over time (in months) for two fulvestrant dose groups: 250 mg and 500 mg. The graph shows curves depicting survival proportions up to 45 months, with a table below indicating the number of patients at risk at various time points for each dose group.*

FDA Label Image

M01 Fig 08

A Kaplan-Meier survival curve chart showing the proportion of patients alive over time (months) for two Fulvestrant dosage groups: 500 mg and 250 mg. The x-axis represents time in months up to 80 months, and the y-axis shows the proportion of patients alive from 0 to 1. The chart includes numerical data of patients at risk at various time points and indicates censored observations.*

FDA Label Image

Figure 9 (M01 Fig 09)

A Kaplan-Meier survival curve chart depicting the probability of progression-free survival (PFS) over time in months from randomization. The chart compares two treatments: Fulvestrant 500 mg and Anastrozole 1 mg, with sample sizes of 230 and 232 patients respectively. The y-axis shows the probability of PFS, and the x-axis represents time in months. Data points and risk tables are shown below the graph.*

FDA Label Image

Figure 10 (M01 Fig 10)

A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time in months. It compares two groups: fulvestrant plus palbociclib and fulvestrant plus placebo. The chart includes a table of the number of patients at risk at various months for each group.*

FDA Label Image

Figure 11 (M01 Fig 11)

A Kaplan-Meier curve showing overall survival probability over time (months) for patients treated with fulvestrant plus palbociclib compared to fulvestrant plus placebo. The graph illustrates declining survival probabilities from 0 to 48 months, with both treatment groups represented by separate lines and patient numbers at risk displayed below the x-axis.*

FDA Label Image

Figure 12 (M01 Fig 12)

A Kaplan-Meier curve chart depicting progression-free survival probability (%) over time in months for two groups: one receiving Fulvestrant plus Abemaciclib and the other receiving Fulvestrant plus Placebo. The chart includes censored observations and patient counts at risk at various time points for both groups.*

FDA Label Image

M01 Fig 13

A Kaplan-Meier survival curve showing survival probability (%) versus time (months) for two groups: patients treated with Fulvestrant plus Abemaciclib and patients treated with Fulvestrant plus Placebo. The graph includes censored observations and the number of patients at risk over time for each group.*

FDA Label Image

M01 Fig 14

A Kaplan-Meier survival curve graph comparing event-free probability over time in months for two groups: Fulvestrant combined with Ribociclib (N=484) and Fulvestrant combined with Placebo (N=242). The graph includes a time axis (months), event-free probability axis (%), and a table of patients at risk below the x-axis.*

FDA Label Image

M01 Fig 15

A Kaplan-Meier survival curve chart showing event-free probability over time (up to 48 months) comparing two groups: Fulvestrant plus Ribociclib versus Fulvestrant plus Placebo. The graph includes a legend for censoring times and the number of patients at risk at various time points.*

FDA Label Image

M01 Fig 16

Packaging label for Fulvestrant Injection 250 mg/5 mL (50 mg/mL) intramuscular injection by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. The carton includes two single-dose prefilled syringes, each containing 250 mg/5 mL of fulvestrant, for a total 500 mg dose. The label features dosage instructions, storage requirements (refrigerate 2-8°C, protect from light), administration guidelines, and safety information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.